Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Oct 21, 2022 1:57pm
206 Views
Post# 35039547

RE:RE:PMN will tank by Years End

RE:RE:PMN will tank by Years EndNot sure where it is going to be by year end, but 95% of people on this board are not all long term holders. The same copy and paste speech of risk..........over the years means nothing to a lot of investors except being mislead and the loss of control and ownership to the Boston group. The Boston group just laughes it up, we will just feed information to our LEAKERS to keep them quiet for a while and they will run with what ever we say.   

Aug 25, 2021 Closes US $20,125,000 to Boston Group. Intended for PMN 310 IND filing, expand the companies porforlio of antibodies and patents, to establish a discovery lab in Boston. 
Sep 30, 2021 - Qtr ended our cash will finance the company's operations into 2024.
Dec 31, 2021- Qtr our cash is sufficient to finance the  operations through the end of 2023
Mar 31 2022- Qtr expect our cash is sufficient to finance the operations through end of 2023
Jun 30 2022- Qtr We expect our cash is sufficient to finance the operations for the next                   
                            twelve months

It's not that hard for a lot of people to see what is happening with the Boston group, financing's don't even go to the public anymore straight to the group. Be prepared for more future financings to this group and then the squeeze out of remaining investors. Do the math what the Boston group ownership was when they first entered compared to now. 


<< Previous
Bullboard Posts
Next >>